# SHR-A1811 Combined with Apatinib in the Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer

> **NCT06666166** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Yunpeng Liu** · enrollment: 28 (estimated)

## Conditions studied

- Advanced Gastric Carcinoma
- Advanced Gastroesophageal Junction Adenocarcinoma
- Advanced Colorectal Cancer

## Interventions

- **DRUG:** SHR-A1811 & Apartinib

## Key facts

- **NCT ID:** NCT06666166
- **Lead sponsor:** Yunpeng Liu
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-12
- **Primary completion:** 2028-07
- **Final completion:** 2028-12
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2024-10-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06666166

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06666166, "SHR-A1811 Combined with Apatinib in the Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06666166. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*